Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in zucker fatty rats

Diabetes

Volumn 47, Issue 8, 1998, Pages 1326-1334

  Buckingham, Robin E ^a   Al Barazanji, Kamal A ^a   Toseland, C D Nigel ^a   Slaughter, Mark ^a   Connor, Susan C ^a   West, Andrew ^a   Bond, Brian ^a   Turner, Nicholas C ^a   Clapham, John C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; N ACETYL BETA GLUCOSAMINIDASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; ROSIGLITAZONE; SERUM ALBUMIN; UNCLASSIFIED DRUG;

AGONIST; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DETERIORATION; DIABETIC NEPHROPATHY; DRUG EFFECT; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; HYPERINSULINEMIA; INTERSTITIAL NEPHRITIS; KIDNEY TUBULE DISORDER; MALE; MICROALBUMINURIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL HYPERPLASIA; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

ACETYLGLUCOSAMINIDASE; ALBUMINURIA; ANIMALS; BLOOD PRESSURE; BODY WEIGHT; HISTOCYTOCHEMISTRY; HYPOGLYCEMIC AGENTS; IMMUNOHISTOCHEMISTRY; ISLETS OF LANGERHANS; KIDNEY; KIDNEY DISEASES; MALE; OBESITY; PANCREAS; PANCREATIC DISEASES; PROTEINURIA; RATS; RATS, ZUCKER; SYSTOLE; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0031847401     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.47.8.1326     Document Type: Article

References (38)

1. Niskanen L, Laakso M: Insulin resistance is related to albuminuria in patients with type II (non-insulin-dependent) diabetes mellituss. Metabolism 42:1541-1545, 1993
2. Haffner SM, Stern MP, Gruber MKK, Hazuda HP, Mitchell BD, Patterson JK: Microalbuminuria: potential marker for increased cardiovascular risk factors in nondiabetic subjects? Arteriosclerosis 10:727-731, 1990
3. Haffner SM, Gonzales C, Valdez RA, Mykkanen L, Hazuda HP, Mitchell BD, Monterrosa A, Stem MP: Is microalbumimiria part of the prediabetic state? The Mexico City Diabetes Study. Diabetologia 36:1002-1006, 1993
4. Mogensen CE: Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Enyl J Med 310:356-300, 1984
5. Yudkin JS, Forrest RD, Jackson CA: Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Lancet 1:530-533, 1988
6. G. Young PW, Cawthorne MA, Coyle PJ, Holder JC, Holman GD, Kozka IJ, Kirkham DM, Lister CA, Smith SA: Repeat treatment of obese mice with BRL 49653, a new and potent insulin sensitizer, enhances insulin action in white adipocytes: association with increased insulin binding and cell surface GLUT 4 as measured by photoaffinity labeling. Diabetes 44:1087-1092, 1995
7. Sreenan S, Stuns J, Pugh W, Burant CF, Polonsky KS: Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. Am J Physiol 271:E742-E747, 1996
8. Kemnitz JW, Elson DF, Roecker EB, Baum ST, Bergman RM, Meglasson MD: Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure in obese, insulin-resistant rhesus monkeys. Diabetes 43:204-211, 1994
9. Patel J, Miller E, Hu J, Granett J: BRL 49653 (a thiazolidmedione) improves glycemic control in NIDDM patients (Abstract). Diabetes 46 (Suppl. 1):150A, 1997
10. Iwamoto Y, Kuzuya T, Matsuda H, Awata T, Kumakura S, Inooka G, Shiraishi I: Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-1086, 1991
11. Wasada T, Omori Y, Sasaki H, Kawamori R, Yamasaki Y, Baba S, Shichiri M, Kaneko T: Effect of pioglitazone (AD-4833) on insulin-stimulated glucose disposal in NIDDM: an assessment by the euglycemic hyperinsulinetmic clamp method. Diabetes 45 (Suppl 2):73A, 1996
12. Larsson L-I, Boder GB, Shaw WN: Changes in the islets of Langerhans in the obese Zucker rat. Lab Invest 36:593-598, 1977
13. Kasiske BL, Cleary MP, O'Donnell MP, Keane WF: Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 106:598-604, 1985
14. Smith SA, Coyle PJ, Cawthorne MA, Holder JC, Kirkham D, Lister CA, Murphy GJ, Young PW: BRL 49653 normalises glycaemic control in Zucker fa/fa rats by improving hepatic and peripheral sensitivity to insulin. Diabetologia 36 (Suppl 1):A184, 1993
15. Wang Q, Dryden S, Frankish HM, Bing C, Pickavance L, Hopkins D, Buckingham R, Williams G: Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y. Br J Pharmacol 122:1405-1410, 1997
16. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Effects of reduced renal mass on tissue lipids and renal injury in hyperlipidemic rats. Kidney Int 35:40-47, 1989
17. Patterson HD, Thompson R: Recovery of inter-block information when block sizes are unequal. Biometrika 58:545-554, 1971
18. Robinson DL, Thompson R, Digby PGN: REML: a program for the analysis of non-orthogonal data by restricted maximum likelihood. Compstat 1982. Proceedings in Computational Statistics, Part II (Suppl). Vienna, Physica Verlag, 1982, p. 231-232
19. Genstat 5 Committee of the Statistics Department, Rothamsted Experimental Station: Genstat 5 Release 3 Reference Manual Payne RW, Lane PW, Eds. Oxford Science Publications, Oxford, U.K., Clarendon Press, 1993, p. 539-583
20. Senn SJ, Auclair P: The graphical representation of clinical trials with particular reference to measurement over time. Stat Med 9:1287-1302, 1990
21. Magil AB: Tubulointerstitial lesions in young Zucker rats. Am J Kidney Dis 25:478-485, 1995
22. Kamanna VS, Kirschenbaum MA: Association between very-low-density lipoprotein and glomerular injury in obese Zucker rats. Am J Nephrol 13:53-58, 1993
23. O'Donnell MP, Kasiske BL, Cleary MP, Keane WF: Effects of genetic obesity on renal structure and function in the Zucker rat. II. Micropuncture studies. J Lab Clin Med 106:605-610, 1985
24. Schmitz PG, O'Donnell MP, Kasiske BL, Katz SA, Keane WF: Renal injury in obese Zucker rats: glomerular haemodynamic alterations and effects of enalapril. Ant J Physiol 263:F496-F502, 1992
25. Crary GS, Swan SK, O'Donnell MP, Kasiske BL, Katz SA, Keane WF: The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats. J Am Soc Nephrol 6:1295-1299, 1995
26. Cantello BCC, Cawthorne MA, Haigh D, Hindley RM, Smith SA, Thurlby PL: The synthesis of BRL 49653-a novel and potent antihyperglycaemic agent. Bioorg Med Chem Lett 4:1181-1184, 1994
27. Cantello BCC, Cawthorne MA, Cottam GP, Duff PT, Haigh D, Hindley RM, Lister CA, Smith SA, Thurlby PL: [[ω-(Heterocyclylamino)alkoxy]benzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J Med Chem 37:3977-3985, 1994
28. Paczek L, Teschner M, Schaefer RM, Heidland A: Intraglomerular fibronectin accumulation and degradation in obese Zucker rats. Diabetologia 34:786-789, 1991
29. Magil AB, Frohlich JJ: Monocytes and macrophages in focal glomerulosclerosis in Zucker rats. Nephron 59:131-138, 1991
30. Gauss-Muller V, Kleinmann HK, Martin GR, Schiffmann E: Role of attachment factors and attractants in fibroblast chemotaxis. J Lab Clin Med 96:1071-1080, 1980
31. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667-672, 1988
32. O'Donnell MP, Kasiske BL, Kim Y, Schmitz PG, Keane WF: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 22:80-89, 1993
33. Yoshioka S, Nishino H, Shiraki T, Ikeda K, Koike H, Okuno A, Wada M, Fujiwara T, Horikoshi H: Antihypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 42:75-80, 1993
34. Kasiske BL, O'Donnell MP, Lee H, Kim Y, Keane WF: Impact of dietary fatty acid supplementation on renal injury in obese Zucker rats. Kidney Int 39:1125-1134, 1991
35. Lehman JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA: An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J Biol Chem 270:12953-12956, 1995
36. Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W: Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat. Endocrinology 137:354-366, 1996
37. Lemmonier D, Aubert R, Suquet J-P, Rosselin G: Metabolism of genetically obese rats on normal or high-fat diet. Diabetologia 10:697-701, 1974
38. Laburthe M, Rancon F, Freychet P, Rosselin G: Glucagon and insulin from lean rats and genetically obese fatty rats: studies by radioimmunoassay, radioreceptorassay and bioassay. Diabetologia 11:517-526, 1975